Zaltrap Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com

RnRMarketResearch.com adds “Zaltrap (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market.

Dallas, TX (PRWEB) December 23, 2014 -- Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. In 2012 Sanofi/Regeneron’s Zaltrap (ziv-aflibercept) was approved by the FDA in combination with FOLFIRI for the treatment of metastatic CRC that has become resistant or progressed on prior oxaliplatin-containing combination therapy. This was followed by European approval in February 2013. Complete Report is Available @ http://www.rnrmarketresearch.com/zaltrap-colorectal-cancer-forecast-and-market-analysis-to-2023-market-report.html.

In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Reasons to Buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Zaltrap performance
• Obtain sales forecast for Zaltrap from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK Japan, and China)


Table of Contents
1 Table of Contents
1.1 List of Tables
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb.
If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears here - PRWeb ebooks - Another online visibility tool from PRWeb.
Contact Information
Ritesh Tiwari
RnR Market Research
http://www.rnrmarketresearch.com/
+1 (888) 391-5441

Online Web 2.0 Version
You can read the online version of this press release here.